EGF Receptor as a Drug Target in Arterial Hypertension

被引：18

作者：

Beltowski, J. ^{[1
]}

Lowicka, E. ^{[1
]}

机构：

[1] Med Univ, Dept Pathophysiol, PL-20090 Lublin, Poland

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2009年 / 9卷 / 05期

关键词：

Epidermal growth factor receptor; arterial hypertension; receptor transactivation; extracellular signal-regulated kinases; receptor tyrosine kinase inhibitors; leptin; metabolic syndrome; EPIDERMAL-GROWTH-FACTOR; VASCULAR SMOOTH-MUSCLE; ACTIVATED PROTEIN-KINASE; LEPTIN-INDUCED HYPERTENSION; BLOOD-PRESSURE REGULATION; RABBIT AORTIC RINGS; HEPARIN-BINDING EGF; ANGIOTENSIN-II; MINERALOCORTICOID RECEPTOR; COUPLED RECEPTORS;

D O I：

10.2174/138955709788167619

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Drugs which inhibit epidermal growth factor receptor (EGFR) are used in the treatment of cancers. EGFR may contribute to the development of hypertension by regulating vascular tone and renal Na+ handling. Synthetic EGFR inhibitors reduce blood pressure in some experimental models of hypertension suggesting that this receptor is a novel target for antihypertensive therapy.

引用

页码：526 / 538

页数：13

共 126 条

[1] Arachidonic acid induces ERK activation via Src SH2 domain association with the epidermal growth factor receptor [J].

Alexander, L. D. ;

Ding, Y. ;

Alagarsamy, S. ;

Cui, X-L ;

Douglas, J. G. .

KIDNEY INTERNATIONAL, 2006, 69 (10) :1823-1832

[2] Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy [J].

Asakura, M ;

Kitakaze, M ;

Takashima, S ;

Liao, Y ;

Ishikura, F ;

Yoshinaka, T ;

Ohmoto, H ;

Node, K ;

Yoshino, K ;

Ishiguro, H ;

Asanuma, H ;

Sanada, S ;

Matsumura, Y ;

Takeda, H ;

Beppu, S ;

Tada, M ;

Hori, M ;

Higashiyama, S .

NATURE MEDICINE, 2002, 8 (01) :35-40

[3] Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension [J].

Beltowski, J ;

Wójcicka, G ;

Marciniak, A ;

Jamroz, A .

LIFE SCIENCES, 2004, 74 (24) :2987-3000

[4]

Beltowski J, 2006, J HYPERTENS, V24, P789

[5] Amphiregulin:: A new growth factor in hepatocarcinogenesis [J].

Berasain, C. ;

Castillo, J. ;

Perugorria, M. J. ;

Prieto, J. ;

Avila, M. A. .

CANCER LETTERS, 2007, 254 (01) :30-41

[6] EPIDERMAL GROWTH-FACTOR, A VASCULAR SMOOTH-MUSCLE MITOGEN, INDUCES RAT AORTIC CONTRACTION [J].

BERK, BC ;

BROCK, TA ;

WEBB, RC ;

TAUBMAN, MB ;

ATKINSON, WJ ;

GIMBRONE, MA ;

ALEXANDER, RW .

JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (03) :1083-1086

[7] H2O2 and Src-dependent transactivation of the EGF receptor mediates the stimulatory effect of leptin on renal ERK and Na+, K+-ATPase [J].

Bettowski, J. ;

Wojcicka, G. ;

Trzeciak, J. ;

Marciniak, A. .

PEPTIDES, 2006, 27 (12) :3234-3244

[8] c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function [J].

Biscardi, JS ;

Maa, MC ;

Tice, DA ;

Cox, ME ;

Leu, TH ;

Parsons, SJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (12) :8335-8343

[9] Angiotensin II-induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptor [J].

Bokemeyer, D ;

Schmitz, U ;

Kramer, HJ .

KIDNEY INTERNATIONAL, 2000, 58 (02) :549-558

[10] Role of heregulin in human cancer [J].

Breuleux, M. .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2007, 64 (18) :2358-2377

← 1 2 3 4 5 6 7 8 9 10 →